Sorafenib and Vorinostat Kill Colon Cancer Cells by CD95-Dependent and -Independent Mechanisms

We examined the interaction between the multikinase inhibitor sorafenib and histone deacetylase inhibitors. Sorafenib and vorinostat synergized (sorafenib + vorinostat) to kill HCT116 and SW480 cells. In SW480 cells, sorafenib + vorinostat increased CD95 plasma membrane levels and promoted death-inducing signal complex (DISC) formation, and drug toxicity was blocked by knockdown of CD95 or overexpression of cellular FLICE-like inhibitory protein (c-FLIP-s). In SW620 cells that are patient-matched to SW480 cells, sorafenib + vorinostat toxicity was significantly lower, which correlated with a lack of CD95 activation and lower expression of ceramide synthase 6 (LASS6). Overexpression of LASS6 in SW620 cells enhanced drug-induced CD95 activation and enhanced tumor cell killing, whereas knockdown of LASS6 in SW480 cells suppressed CD95 activation. Knocking down LASS6 expression also suppressed CD95 activation in hepatoma, pancreatic, and ovarian cancer cells. In HCT116 cells, sorafenib + vorinostat treatment caused DISC formation without reducing c-FLIP-s expression and did not increase CD95 plasma membrane levels; sorafenib + vorinostat exposure killed HCT116 cells via an intrinsic pathway/caspase 9-dependent mechanism. In HCT116 cells, knockdown of CD95 enhanced sorafenib + vorinostat lethality, which correlated with less drug-induced CD95-dependent autophagy. Sorafenib + vorinostat treatment activated the c-Jun NH2-terminal kinase pathway, which was causal in promoting dissociation of Beclin1 from BCL-2, and in promoting autophagy. Knockdown of Beclin1 expression blocked autophagy and enhanced drug toxicity. Our data demonstrate that treatment of colon cancer cells with sorafenib + vorinostat activates CD95 via de novo ceramide synthesis that promotes viability via autophagy or degrades survival via either the extrinsic or intrinsic pathways.

[1]  P. Lu,et al.  Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase 3 in colon cancer cells , 2008, Oncogene.

[2]  P. Fisher,et al.  Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation , 2008, Cancer biology & therapy.

[3]  John D. Roberts,et al.  Vorinostat and Sorafenib Synergistically Kill Tumor Cells via FLIP Suppression and CD95 Activation , 2008, Clinical Cancer Research.

[4]  P. Fisher,et al.  Lapatinib Resistance in HCT116 Cells Is Mediated by Elevated MCL-1 Expression and Decreased BAK Activation and Not by ERBB Receptor Kinase Mutation , 2008, Molecular Pharmacology.

[5]  P. Fisher,et al.  Mitogen-activated protein kinase kinase 1/2 inhibitors and 17-allylamino-17-demethoxygeldanamycin synergize to kill human gastrointestinal tumor cells in vitro via suppression of c-FLIP-s levels and activation of CD95 , 2008, Molecular Cancer Therapeutics.

[6]  S. Pattingre,et al.  JNK1-mediated phosphorylation of Bcl-2 regulates starvation-induced autophagy. , 2008, Molecular cell.

[7]  P. Fisher,et al.  OSU-03012 Stimulates PKR-Like Endoplasmic Reticulum-Dependent Increases in 70-kDa Heat Shock Protein Expression, Attenuating Its Lethal Actions in Transformed Cells , 2008, Molecular Pharmacology.

[8]  M. Czaja,et al.  Loss of Macroautophagy Promotes or Prevents Fibroblast Apoptosis Depending on the Death Stimulus*♦ , 2008, Journal of Biological Chemistry.

[9]  P. Fisher,et al.  Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells , 2008, Molecular Cancer Therapeutics.

[10]  J. Lynch,et al.  Systemic and targeted therapy for advanced colon cancer , 2008, Expert review of gastroenterology & hepatology.

[11]  Laurent Bélec,et al.  Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis , 2007, Proceedings of the National Academy of Sciences.

[12]  R. Poon,et al.  From Molecular Biology to Targeted Therapies for Hepatocellular Carcinoma: The Future Is Now , 2007, Oncology.

[13]  Paul Dent,et al.  The Multikinase Inhibitor Sorafenib Induces Apoptosis in Highly Imatinib Mesylate-Resistant Bcr/Abl+ Human Leukemia Cells in Association with Signal Transducer and Activator of Transcription 5 Inhibition and Myeloid Cell Leukemia-1 Down-Regulation , 2007, Molecular Pharmacology.

[14]  P. Hersey,et al.  Apoptosis Induction in Human Melanoma Cells by Inhibition of MEK Is Caspase-Independent and Mediated by the Bcl-2 Family Members PUMA, Bim, and Mcl-1 , 2007, Clinical Cancer Research.

[15]  Paul D. Martin,et al.  AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models , 2007, Molecular Cancer Therapeutics.

[16]  P. Dent,et al.  Synergistic Interactions between Vorinostat and Sorafenib in Chronic Myelogenous Leukemia Cells Involve Mcl-1 and p21CIP1 Down-Regulation , 2007, Clinical Cancer Research.

[17]  Nanxin Li,et al.  B-Raf kinase inhibitors for cancer treatment. , 2007, Current opinion in investigational drugs.

[18]  M. Gregor,et al.  Epigenetic combination therapy as a tumor‐selective treatment approach for hepatocellular carcinoma , 2007, Cancer.

[19]  K. Flaherty.  Sorafenib: delivering a targeted drug to the right targets , 2007, Expert review of anticancer therapy.

[20]  P. Fisher,et al.  Radiation-induced cell signaling: inside-out and outside-in , 2007, Molecular Cancer Therapeutics.

[21]  K. Turner,et al.  Assessment of developmental toxicity of vorinostat, a histone deacetylase inhibitor, in Sprague-Dawley rats and Dutch Belted rabbits. , 2007, Birth defects research. Part B, Developmental and reproductive toxicology.

[22]  P. Dent,et al.  17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines , 2007, Molecular Cancer Therapeutics.

[23]  M. Czaja,et al.  Tumor Necrosis Factor-induced Toxic Liver Injury Results from JNK2-dependent Activation of Caspase-8 and the Mitochondrial Death Pathway* , 2006, Journal of Biological Chemistry.

[24]  M. Kohno,et al.  Blockade of the ERK pathway markedly sensitizes tumor cells to HDAC inhibitor-induced cell death. , 2006, Biochemical and biophysical research communications.

[25]  Dirk Strumberg,et al.  Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. , 2005, Drugs of today.

[26]  J. Gollob.  Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. , 2005, Clinical genitourinary cancer.

[27]  P. Dent,et al.  Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation* , 2005, Journal of Biological Chemistry.

[28]  P. Dent,et al.  Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL+ human leukemia cells , 2005, Leukemia.

[29]  H. Yamaguchi,et al.  Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2 , 2005, Clinical Cancer Research.

[30]  H. Riezman,et al.  The ins and outs of sphingolipid synthesis. , 2005, Trends in cell biology.

[31]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[32]  Y. Minemoto,et al.  c-Jun N-Terminal Protein Kinase 1 (JNK1), but Not JNK2, Is Essential for Tumor Necrosis Factor Alpha-Induced c-Jun Kinase Activation and Apoptosis , 2004, Molecular and Cellular Biology.

[33]  Yusuf A. Hannun,et al.  Biologically active sphingolipids in cancer pathogenesis and treatment , 2004, Nature Reviews Cancer.

[34]  P. Dent,et al.  Kinase Inhibitors and Cytotoxic Drug Resistance , 2004, Clinical Cancer Research.

[35]  Paul Dent,et al.  MAPK pathways in radiation responses , 2003, Oncogene.

[36]  Z. Fuks,et al.  Radiation and ceramide-induced apoptosis , 2003, Oncogene.

[37]  B. Groner,et al.  The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2 , 2003, The EMBO journal.

[38]  P. Clarke,et al.  Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK , 2003, Nature Cell Biology.

[39]  M. Peter,et al.  The CD95 type I/type II model. , 2003, Seminars in immunology.

[40]  S. Cook,et al.  Activation of the ERK1/2 Signaling Pathway Promotes Phosphorylation and Proteasome-dependent Degradation of the BH3-only Protein, Bim* , 2003, Journal of Biological Chemistry.

[41]  D. Conrad,et al.  Induction of Apoptosis in BCR/ABL+ Cells By Histone Deacetylase Inhibitors Involves Reciprocal Effects on the RAF/MEK/ERK and JNK Pathways , 2003, Cancer biology & therapy.

[42]  K. Ozawa,et al.  Activation of extracellular signal‐regulated kinases ERK1 and ERK2 induces Bcl‐xL up‐regulation via inhibition of caspase activities in erythropoietin signaling , 2003, Journal of cellular physiology.

[43]  P. Dent,et al.  Bile Acid Regulation of C/EBPβ, CREB, and c-Jun Function, via the Extracellular Signal-Regulated Kinase and c-Jun NH2-Terminal Kinase Pathways, Modulates the Apoptotic Response of Hepatocytes , 2003, Molecular and Cellular Biology.

[44]  E. Wagner,et al.  Differential effects of JNK1 and JNK2 on signal specific induction of apoptosis , 2002, Oncogene.

[45]  P. Dent,et al.  Inhibition of the MAPK and PI3K pathways enhances UDCA‐induced apoptosis in primary rodent hepatocytes , 2002, Hepatology.

[46]  G. Bae,et al.  Apicidin, a Histone Deacetylase Inhibitor, Induces Apoptosis and Fas/Fas Ligand Expression in Human Acute Promyelocytic Leukemia Cells* , 2002, The Journal of Biological Chemistry.

[47]  P. Fisher,et al.  Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis. , 2001, Molecular biology of the cell.

[48]  P. Gregory,et al.  Histone acetylation and chromatin remodeling. , 2001, Experimental cell research.

[49]  K. Zänker,et al.  Differences in the migration capacity of primary human colon carcinoma cells (SW480) and their lymph node metastatic derivatives (SW620). , 1998, Cancer letters.

[50]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[51]  G. Mills,et al.  Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. , 2009, Cancer research.

[52]  R. Vento,et al.  The role of oxidative stress in apoptosis induced by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in human colon adenocarcinoma HT-29 cells. , 2008, International journal of oncology.

[53]  C. Trautwein,et al.  Signaling Pathways in Liver Diseases , 2008 .

[54]  P. Fisher,et al.  OSU-03012 stimulates PERK-dependent increases in HSP 70 expression , attenuating its lethal actions in transformed cells , 2007 .

[55]  P. Dent.  MAP Kinase Pathways in the Control of Hepatocyte Growth, Metabolism and Survival , 2005 .